newsfilter
← Latest News
Business Wire·

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses -- Horizon Therapeutics plc (NASDAQ:HZNP) today announced that new UPLIZNA analyses will be presented at